AzTrials
AzTrials

Patent Foramen OvaleNCT04549272

Assessment of Early Vascular Damage With Advanced Neuroimaging in Patient With Patent Foramen Ovale

An observational study of Patent Foramen Ovale, run by Neuromed IRCCS.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Patent foramen ovale arises from the incomplete postnatal fusion of the septum primum and secundum and can cause paradoxical embolism in adults. In case of cerebral ischemic stroke, the correlation with the patent foramen ovale is based on probabilistic approach. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Patent Foramen Ovale
How many people
100 participants
Where
No sites listed yet
Study dates
Oct 2022to Oct 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Subjects will be selected from patients attending the Department of AngioCardioNeurology of the IRCCS Neuromed, accordingly to the following inclusion/exclusion criteria. Approximately 100 subjects of both genders will be included in the study.

Who may be able to join

  • age ≥ 18 and ≤ 65 years
  • patients with patent foramen ovale
  • written informed consent

Who cannot join

  • previous IMA, stroke or TIA
  • arrhythmia or severe cardiac disease
  • hypertension, diabetes or renal disease
  • psychiatric disease
  • neurological or neurodegenerative disease
  • dementia
Show all 9Show fewer
  • assumption of drugs known to interfere with cognitive function
  • inability to be subjected MRI analysis
  • participation to other clinical trial, ongoing or terminated less than one month before enrolment in this study.

Trial locations and contacts

No sites are listed yet.

Giuseppe Lembo, MD, PhD contact

+390865915225

lembo@neuromed.it

About this study

Patent foramen ovale arises from the incomplete postnatal fusion of the septum primum and secundum and can cause paradoxical embolism in adults. In case of cerebral ischemic stroke, the correlation with the patent foramen ovale is based on probabilistic approach. For this reason, continuous research is indispensable, especially according to new approaches, to offer tools capable of guiding in case of adverse event with greater certainty and even better to prevent it. Thus, this study aims to: 1) evaluate the microstructural brain damage through advanced MRI analysis in patients with patent foramen ovale; 2) evaluate how much the degree of the shunt can affect brain damage. In order to do this, this study aims to evaluate advanced brain imaging in a cohort of patients with patent foramen ovale to identify the development of early vascular damage.

Being tested
No interventions
Keywords
Magnetic Resonance Imaging, Vascular Cognitive Impairment
Medical subject headings
Foramen Ovale, Patent

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No interventionsOther

    No interventions - observational study

Study groups in NCT04549272
Study groupRoleWhat they receive
Patients with Patent Foramen OvaleNot described
Receives: Other: No interventions

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measurement of percentage change in diffusion parameters of the white matter

    Fiber tracking by DTI MRI

    Measured: At Enrollment

Secondary outcomes (3)
  1. Quantification of the degree of shunt of the patent foramen ovale

    Echography

    Measured: At Enrollment

  2. Detection of cognitive decline by decrease of MoCA score

    Cognitive tests

    Measured: At Enrollment

  3. Detection of a non-invasive retinal screening

    Digital ophthalmoscope

    Measured: At Enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Sep 2020
  2. Study startOct 2022 (estimated)
  3. Primary completionOct 2023 (estimated)
  4. Study completionOct 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04549272
Sponsor's protocol ID
LMB08
Status last verified
Apr 2022
First submitted
8 Sep 2020
Last updated
11 Apr 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Patent Foramen Ovale, run by Neuromed IRCCS.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Giuseppe Lembo, MD, PhD (+390865915225, lembo@neuromed.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measurement of percentage change in diffusion parameters of the white matter (time frame: At Enrollment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in